Business News • PR NewsWire • Targovax and Valo Therapeutics Enter Collaboration to Develop RAS Neoantigen Coating of ONCOS Viruses Using PeptiCRAd Technology

Targovax and Valo Therapeutics Enter Collaboration to Develop RAS Neoantigen Coating of ONCOS Viruses Using PeptiCRAd Technology

Targovax and Valo Therapeutics Enter Collaboration to Develop RAS Neoantigen Coating of ONCOS Viruses Using PeptiCRAd Technology

OSLO, Norway, and HELSINKI, April 22, 2020 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses and cancer vaccines to target hard-to-treat solid tumors, and Valo Therapeutics (Valo Tx) today announce that they have entered into a...

View More : https://www.prnewswire.com:443/news-releases/targovax-and-valo-therapeutics-enter-collaboration-to-develop-ras-neoantige...

Releted News by prnewswire

Interim Report For The First Quarter 2020 New Wave Group AB

Precision For Medicine совместно с Karyopharm Therapeutics инициируют новое глобальное клиническое исследование в области COVID-19

Annual General Meeting in Oncopeptides AB (publ)

Bioplastics Innovations Lagging Behind Public Sentiment for Sustainable Plastics Alternatives, Says New Clarivate Report